Targeting wildtype and L858R/T790M mutant EGFR by isoliquiritigenin induces apoptosis and Inhibits tumor growth of NSCLC

被引：0

作者：

Lee, Mee-Hyun ^{[1
]}

Jung, Sung Keun ^{[2
]}

Lim, Do Young ^{[3
]}

Cho, Yong-Yeon ^{[1
]}

Lee, Cheol-Jung ^{[1
]}

Song, Ji-Hong ^{[1
]}

Kim, Myoung Ok ^{[4
]}

Kim, Sung-Hyun ^{[4
]}

Bode, Ann M. ^{[3
]}

Dong, Zigang ^{[3
]}

机构：

[1] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea

[2] Korea Food Res Inst, Div Metab & Funct Res, Songnam, South Korea

[3] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA

[4] Kyungpook Natl Univ, Ctr Lab Anim Resources, Sch Anim BT Sci, Daegu, South Korea

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

10.1158/1538-7445.AM2015-1917

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1917

引用

页数：1

共 50 条

[1] Isoliquiritigenin Induces Apoptosis and Inhibits Xenograft Tumor Growth of Human Lung Cancer Cells by Targeting Both Wild Type and L858R/T790M Mutant EGFR
Jung, Sung Keun
Lee, Mee-Hyun
Lim, Do Young
Kim, Jong Eun
Singh, Puja
Lee, Sung-Young
Jeong, Chul-Ho
Lim, Tae-Gyu
Chen, Hanyong
Chi, Young-In
Kundu, Joydeb Kumar
Lee, Nam Hyouck
Lee, Charles C.
Cho, Yong-Yeon
Bode, Ann M.
Lee, Ki Won
Dong, Zigang
JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (52) : 35839 - 35848
[2] Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S
Wang, Tong-Hong
Leu, Yann-Lii
Chen, Chin-Chuan
Li, Hsin-Jung
Yang, Shuenn-Chen
Huang, Kuo-Yen
Chen, Chi-Yuan
PHYTOTHERAPY RESEARCH, 2022, 36 (05) : 2116 - 2126
[3] Detection of EGFR Mutations T790M and L858R for Therapeutic Guidance of NSCLC
Rana, M.
Asil, S. M.
Boutin, C.
Kachwala, M. J.
Espejo, J.
Argun, A. A.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S496 - S496
[4] Discovery and optimization of covalent EGFR T790M/L858R mutant inhibitors
Hoogenboom, Niels
Demont, Dennis
de Zwart, Edwin
Verkaik, Saskia
Emmelot, Maaike
van de Kar, Bas
Kaptein, Allard
Barf, Tjeerd
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2021, 52
[5] Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R/T790 mutants
Saldana-Rivera, Lucia
Bello, Martiniano
Mendez-Luna, David
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (17): : 4671 - 4684
[6] QSAR of clinically important EGFR mutant L858R/T790M pyridinylimidazole inhibitors
Fatima, Shehnaz
Pal, Divyani
Agarwal, Subhash Mohan
CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 94 (01) : 1306 - 1315
[7] Binding mechanism of kinase inhibitors to EGFR and T790M, L858R and L858R/T790M mutants through structural and energetic analysis
Bello, Martiniano
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2018, 118 : 1948 - 1962
[8] Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR
Todsaporn, Duangjai
Zubenko, Alexander
Kartsev, Victor G.
Mahalapbutr, Panupong
Geronikaki, Athina
Sirakanyan, Samvel N.
Divaeva, Lyudmila N.
Chekrisheva, Victoria
Yildiz, Ilkay
Choowongkomon, Kiattawee
Rungrotmongkol, Thanyada
JOURNAL OF PHYSICAL CHEMISTRY B, 2024, 128 (50): : 12389 - 12402
[9] Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts
Hu, Peng
Han, Da-xiong
Ruan, Run-sheng
Zheng, Li-Mou
Chou, Shiu-Huey
Tzeng, Chi-Meng
ONCOTARGET, 2016, 7 (24) : 35741 - 35752
[10] Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
Wu, Hong
Wang, Aoli
Zhang, Wei
Wang, Beilei
Chen, Cheng
Wang, Wenchao
Hu, Chen
Ye, Zi
Zhao, Zheng
Wang, Li
Li, Xixiang
Yu, Kailin
Liu, Juan
Wu, Jiaxin
Yan, Xiao-E
Zhao, Peng
Wang, Jinhua
Wang, Chu
Weisberg, Ellen L.
Gray, Nathanael S.
Yun, Cai-Hong
Liu, Jing
Chen, Liang
Liu, Qingsong
ONCOTARGET, 2015, 6 (31) : 31313 - 31322

← 1 2 3 4 5 →